CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD⁺ Pools

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Tumor cells exhibit heightened metabolism to support proliferation.
• Nicotinamide adenine dinucleotide (NAD+) is a crucial cofactor in metabolic reactions and a substrate for enzymes like PARPs and sirtuins.
• CD38, a NAD+-consuming enzyme, is dysregulated in various cancers.

Purpose of the Study:

• To investigate the novel connection between CD38, NAD+ modulation, and tumor cell metabolism in prostate cancer.
• To elucidate the role of CD38 in regulating prostate cancer cell proliferation and gene expression.

Main Methods:

• Analysis of CD38 expression in relation to prostate cancer progression.
• Experimental manipulation of CD38 expression in prostate cancer cells to assess effects on NAD+ levels, cell cycle, metabolism, and gene expression.
• Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT) to compare metabolic consequences.

Main Results:

• CD38 expression inversely correlates with prostate cancer progression.
• Increased CD38 expression reduced intracellular NAD+, induced cell-cycle arrest (p21^Cip1 expression), and suppressed glycolytic and mitochondrial metabolism.
• CD38 activation of AMP-activated protein kinase (AMPK) inhibited fatty acid and lipid synthesis.
• NAMPT inhibition mimicked the metabolic effects of CD38 expression.
• CD38 modulated the transcriptome, generating a signature indicative of a nonproliferative phenotype.

Conclusions:

• The CD38-NAD+ axis plays a novel regulatory role in prostate cancer cell metabolism and development.
• This study establishes a mechanistic link between CD38 and metabolic control in cancer.
• Findings support the development of NAD+-modulating agents as potential prostate cancer therapeutics.